|1.||Kundu, Namita: 3 articles (01/2014 - 03/2006)|
|2.||Ma, Xinrong: 3 articles (01/2014 - 03/2006)|
|3.||Goloubeva, Olga: 2 articles (01/2014 - 09/2009)|
|4.||Fulton, Amy M: 2 articles (09/2009 - 03/2006)|
|5.||Kochel, Tyler: 1 article (01/2014)|
|6.||Fulton, Amy: 1 article (01/2014)|
|7.||Reader, Jocelyn: 1 article (01/2014)|
|8.||Thompson, Keyata: 1 article (01/2014)|
|9.||Staats, Paul: 1 article (01/2014)|
|10.||Martin, Stuart: 1 article (01/2014)|
09/01/1985 - "Late intervention with AH23848, 25 min after the onset of myocardial ischaemia did not significantly alter the incidence of reperfusion-induced ventricular fibrillation; 70% of the control group died and 60% of those that received AH23848. "
01/01/1985 - "The evidence is that in anaesthetised greyhound dogs, blockade of the thromboxane receptor (AH 23848) or inhibition of thromboxane synthesis (with a variety of "specific" inhibitors of thromboxane synthetase such as dazoxiben, dazmegrel, and "low-dose" aspirin) slightly reduces the severity of ischaemia-induced arrhythmias and markedly increases survival after myocardial reperfusion by reducing reperfusion-induced ventricular fibrillation (e.g., from 80% in control dogs to less than 20% in treated dogs). "
12/01/1986 - "The effect of the specific thromboxane receptor blocking drug AH23848 was investigated in two double blind placebo controlled studies in male patients with exercise induced angina pectoris and angiographically verified coronary lesions. "
12/01/1986 - "Effect of the specific thromboxane receptor blocking drug AH23848 in patients with angina pectoris."
09/01/2009 - "The EP4 antagonist AH23848 reduced the ability of tumor cells to colonize the lungs or to spontaneously metastasize from the mammary gland. "
10/01/2008 - "EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth. "
02/01/2012 - "Small tumor slices harvested from four OE33 xenografts were implanted in the flanks of new mice that were randomized to different treatments (6 animals per group): indomethacin (3 mg/kg/day), parecoxib (0.11 and 0.22 mg/kg/day) or a selective prostaglandin E₂ receptor antagonist (AH-23848B, 1 mg/kg/day). "
01/21/2011 - "Blocking PGE(2) synthesis by NS398 or through the use of PGE(2) receptor antagonists AH-6809 (EP2 antagonist) and AH-23848 (EP4 antagonist) completely reversed the inhibitory effect of tumor-conditioned medium (TCM) on LPS-induced CCL5 expression. "
12/01/1986 - "There was no significant difference between the placebo and AH23848 treatment periods in exercise tolerance, the rate-pressure product at angina after exercise testing, the number of ischaemic attacks as determined from 24 hour ambulatory electrocardiograms, the number of attacks of pain, or the number of glyceryl trinitrate tablets consumed. "
12/01/2006 - "Administration of both an EP4 antagonist [AH23848, (4Z)-7-[(rel-1S,2S,5R)-5-((1,1'-biphenyl-4-yl)methoxy)-2-(4-morpholinyl)-3-oxocyclopentyl]-4-heptenoic acid] and EP4 knockdown with intrathecally delivered short hairpin RNA attenuates inflammation-induced thermal and mechanical behavioral hypersensitivity, without changing basal pain sensitivity. "
|5.||Hypertension (High Blood Pressure)
12/01/1989 - "In order to determine whether the increased renal biosynthesis of thromboxane A2, observed in young genetically hypertensive (LH) rats of the Lyon strain, could be involved in the development of their hypertension, 12 LH female rats were given a specific thromboxane A2 receptor antagonist, AH 23848 (Glaxo Group Research) orally (2 mg/kg twice a day) from 3 to 9 weeks of age. "
12/01/1990 - "To determine whether the increased renal biosynthesis of thromboxane A2 observed in young genetically hypertensive rats of the Lyon strain could be involved in the development of their hypertension, Lyon hypertensive female rats received either thromboxane synthetase inhibitors (Dazmegrel or OKY 046) or a thromboxane A2 receptor antagonist (AH 23848) during their prehypertensive stage. "
|1.||Thromboxane Receptors (Thromboxane Receptor)
|4.||Aspirin (Acetylsalicylic Acid)
|6.||Prostaglandin H2 Thromboxane A2 Receptors
|7.||Thromboxane A2 (A2, Thromboxane)
|8.||Prostaglandins E (PGE)
|10.||4- (4- cyano- 2- (2- (4- fluoronaphthalen- 1- yl)propionylamino)phenyl)butyric acid
|1.||Heterologous Transplantation (Xenotransplantation)